These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18806899)

  • 1. Desvenlafaxine succinate for major depressive disorder.
    Sproule BA; Hazra M; Pollock BG
    Drugs Today (Barc); 2008 Jul; 44(7):475-87. PubMed ID: 18806899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
    Pae CU; Park MH; Marks DM; Han C; Patkar AA; Masand PS
    Curr Opin Investig Drugs; 2009 Jan; 10(1):75-90. PubMed ID: 19127490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine succinate for the treatment of major depressive disorder.
    Lohoff FW; Rickels K
    Expert Opin Pharmacother; 2008 Aug; 9(12):2129-36. PubMed ID: 18671467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
    Perry R; Cassagnol M
    Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.
    Nichols AI; Tourian KA; Tse SY; Paul J
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1565-74. PubMed ID: 21067460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
    Seo HJ; Sohi MS; Patkar AA; Masand PS; Pae CU
    Postgrad Med; 2010 Jan; 122(1):125-38. PubMed ID: 20107296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine for the treatment of major depressive disorder.
    Kornstein SG; McIntyre RS; Thase ME; Boucher M
    Expert Opin Pharmacother; 2014 Jul; 15(10):1449-63. PubMed ID: 24914479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
    Kamath J; Handratta V
    Expert Rev Neurother; 2008 Dec; 8(12):1787-97. PubMed ID: 19086875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats.
    Alfinito PD; Huselton C; Chen X; Deecher DC
    Brain Res; 2006 Jul; 1098(1):71-8. PubMed ID: 16764833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
    Dolder C; Nelson M; Stump A
    Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desvenlafaxine: a new antidepressant or just another one?
    Pae CU
    Expert Opin Pharmacother; 2009 Apr; 10(5):875-87. PubMed ID: 19351235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of desvenlafaxine succinate for menopausal hot flashes.
    Tella SH; Gallagher JC
    Expert Opin Pharmacother; 2014 Nov; 15(16):2407-18. PubMed ID: 25252697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
    Jann MW; Spratlin V; Momary K; Zhang H; Turner D; Penzak SR; Wright A; VanDenBerg C
    Eur J Clin Pharmacol; 2012 May; 68(5):715-21. PubMed ID: 22173281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder.
    Lieberman DZ; Montgomery SA; Tourian KA; Brisard C; Rosas G; Padmanabhan K; Germain JM; Pitrosky B
    Int Clin Psychopharmacol; 2008 Jul; 23(4):188-97. PubMed ID: 18545056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
    Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.